Regulation of mitochondrial proliferation in the heart: power-plant failure contributes to cardiac failure in hypertrophy
- PMID: 15485678
- DOI: 10.1016/j.cardiores.2004.06.030
Regulation of mitochondrial proliferation in the heart: power-plant failure contributes to cardiac failure in hypertrophy
Abstract
During hypertrophy, proliferation of mitochondria does not keep pace with the increasing energy demand of the heart. This probably contributes importantly to cardiac failure, together with other phenotypic changes occurring during the growth process. The problem may be even aggravated if defects of mitochondrial function itself and not external factors cause the hypertrophic process. Here we review the basic mechanisms controlling mitochondrial biogenesis, especially the pathways coordinating expression of nuclear encoded mitochondrial genes and the small mitochondrial genome, and how these mechanisms may be connected to the cardiomyocyte differentiation program during development as well as under physiological and pathological circumstances.
Similar articles
-
Mitochondria and Cardiac Hypertrophy.Adv Exp Med Biol. 2017;982:203-226. doi: 10.1007/978-3-319-55330-6_11. Adv Exp Med Biol. 2017. PMID: 28551789 Review.
-
Increased expression and intramitochondrial translocation of cyclophilin-D associates with increased vulnerability of the permeability transition pore to stress-induced opening during compensated ventricular hypertrophy.J Mol Cell Cardiol. 2009 Mar;46(3):420-30. doi: 10.1016/j.yjmcc.2008.10.020. Epub 2008 Nov 6. J Mol Cell Cardiol. 2009. PMID: 19094991
-
Heart spotting.Basic Res Cardiol. 2008 May;103(3):228-31. doi: 10.1007/s00395-008-0698-z. Epub 2008 Feb 15. Basic Res Cardiol. 2008. PMID: 18274799
-
Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure.Clin Exp Pharmacol Physiol. 2007 Apr;34(4):255-62. doi: 10.1111/j.1440-1681.2007.04585.x. Clin Exp Pharmacol Physiol. 2007. PMID: 17324134 Review.
-
Review: Mitochondrial medicine--cardiomyopathy caused by defective oxidative phosphorylation.Ann Clin Lab Sci. 2003 Fall;33(4):371-95. Ann Clin Lab Sci. 2003. PMID: 14584751 Review.
Cited by
-
Growing concerns about using hypoxia-inducible factor prolyl hydroxylase inhibitors for the treatment of renal anemia.Clin Kidney J. 2024 Feb 28;17(3):sfae051. doi: 10.1093/ckj/sfae051. eCollection 2024 Mar. Clin Kidney J. 2024. PMID: 38516524 Free PMC article. Review.
-
High-Density Lipoproteins at the Interface between the NLRP3 Inflammasome and Myocardial Infarction.Int J Mol Sci. 2024 Jan 20;25(2):1290. doi: 10.3390/ijms25021290. Int J Mol Sci. 2024. PMID: 38279290 Free PMC article. Review.
-
Mitochondrial quality control in health and cardiovascular diseases.Front Cell Dev Biol. 2023 Nov 6;11:1290046. doi: 10.3389/fcell.2023.1290046. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 38020895 Free PMC article. Review.
-
Hyperhomocysteinaemia Promotes Doxorubicin-Induced Cardiotoxicity in Mice.Pharmaceuticals (Basel). 2023 Aug 28;16(9):1212. doi: 10.3390/ph16091212. Pharmaceuticals (Basel). 2023. PMID: 37765020 Free PMC article.
-
Effect of diminazene on cardiac hypertrophy through mitophagy in rat models with hyperthyroidism induced by levothyroxine.Naunyn Schmiedebergs Arch Pharmacol. 2024 Feb;397(2):1151-1162. doi: 10.1007/s00210-023-02680-6. Epub 2023 Aug 26. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 37632551
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources